Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Withdrawn 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 25Neoplasms 3Neoplasm Metastasis 3Metastatic Castration-Resistant Prostate Cancer (mCRPC) 2Urogenital Neoplasms 1Prostatic Diseases 1Prostate Cancer Metastatic 1Neoplasms, Glandular and Epithelial 1Metastatic Castration-resistant Prostate Cancer 1Metastatic Castrate-resistant Prostate Cancer 1Hormone-Refractory Prostate Cancer 1Genital Neoplasms, Male 1Carcinoma 1Adenocarcinoma of the Prostate 1Adenocarcinoma 1

Interventions

pembrolizumab 155Gemcitabine 139Capecitabine 121Paclitaxel 118Fluorouracil 116Oxaliplatin 110Bevacizumab 104Nivolumab 97Leucovorin 97Docetaxel 92Cisplatin 89Irinotecan 87Carboplatin 84Radiosurgery 83Cyclophosphamide 70Cetuximab 70Magnetic Resonance Spectroscopy 68Trastuzumab 56Specimen Handling 56Biopsy 56Radiotherapy 55Ipilimumab 52Everolimus 48Pemetrexed 46Drug Therapy 45Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 43Doxorubicin 41Fulvestrant 38aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Neoplasm Metastasis × sipuleucel-T × Clear all
NCT02036918 2020-03-31

Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer

Duke University

Phase 1 Completed
20 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT02793219 2017-10-30

Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer

The University of Texas Health Science Center, Houston

Phase 2 Withdrawn
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT02793765 2017-10-30

Docetaxel Followed by Provenge in Metastatic Prostate Cancer

The University of Texas Health Science Center, Houston

Phase 2 Withdrawn
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡